You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾(06185.HK)新冠疫苗被推薦作為第二劑次加強免疫接種
阿思達克 12-15 05:02
康希諾生物(06185.HK)公布,肌注式重組新冠病毒疫苗(5型腺病毒載體)及吸入用重組新型冠狀病毒疫苗(5型腺病毒載體)被推薦作為第二劑次加強免疫接種,若後續國家相關部門對其採購使用增加,將對業績產生一定的積極影響。 根據國務院「新冠病毒疫苗第二劑次加強免疫接種實施方案通知」,疫苗選擇為優先考慮序貫加強免疫接種,或採用含奧密克戎毒株或對奧密克戎毒株具有良好交叉免疫的疫苗進行第二劑次加強免疫接種,其中,涉及公司的組合包括︰3劑滅活疫苗+1劑肌注式重組新冠病毒疫苗(商品名︰克威莎);3劑滅活疫苗+1劑吸入用重組新冠病毒疫苗(商品名︰克威莎霧優);及2劑克威莎+1劑克威莎霧優。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account